目的 研究白藜芦醇（resveratrol， Res）对激素依赖型和去势抵抗型前列腺癌（PCa）生长的抑制作用及其潜在机制。 方法 采用前列腺癌细胞系LNCaP及其激素抵抗型LNCaP-B细胞系建立裸鼠皮下移植瘤模型。将30只裸鼠分为对照组、白藜芦醇处理组、阳性药物（多西他赛）组。记录移植瘤的生长情况，通过实时荧光定量PCR（qRT-PCR）和Western blot检测移植瘤中雄激素受体（androgen receptor， AR）的mRNA及蛋白表达水平。 结果 中、高剂量的白藜芦醇显著抑制了LNCaP和LNCaP-B移植瘤的生长，且这种抑制表现出剂量依赖性，差异具有统计学意义（P < 0.05）；qRT-PCR和Western blot检测显示，白藜芦醇显著降低了移植瘤中AR的mRNA及蛋白表达水平。 结论 白藜芦醇通过抑制AR的表达和信号通路活性，有效抑制了激素依赖型和激素抵抗型前列腺癌的生长，提示其作为雄激素剥夺疗法（androgen deprivation therapy， ADT）辅助药物的潜力，为其在前列腺癌治疗中的应用提供了理论支持。

Objective To investigate the inhibitory effects of resveratrol （Res） on the growth of hormone-dependent and castration-resistant prostate cancer （PCa） and explore its mechanisms. Methods Subcutaneous xenograft models were established in nude mice using the human prostate cancer cell lines LNCaP （hormone-sensitive） and its castration-resistant derivative LNCaP-B. Thirty nude mice were randomly divided into three groups： control group， Res-treated and docetaxel. Tumor growth was recorded. Quantitative real-time polymerase chain reaction （qRT-PCR） and Western blot were performed to assess androgen receptor （AR） mRNA and protein expression levels in tumor tissues. Results Moderate- and high-dose Res significantly inhibited the growth of both LNCaP and LNCaP-B xenografts in a dose-dependent manner， with statistical significance （P < 0.05）. qRT-PCR and Western blot analyses revealed that Res markedly downregulated AR mRNA expression and protein levels compared to the control group. However， no significant pathological alterations were observed in HE-stained tumor sections. Conclusions Resveratrol suppresses the growth of hormone-dependent and castration-resistant prostate cancer by inhibiting AR expression and signaling pathway activity. These findings highlight its potential as an adjuvant therapeutic agent to androgen deprivation therapy （ADT）， providing a theoretical foundation for its clinical application in PCa treatment.